ONCOLOGY: December 2010 Supplement

Article

Exploring the Clinical Decisions of US Community-Based Oncologists and Hematologists in the Management of Multiple Myeloma and Follicular LymphomaSupported by educational grants from Celgene Corporation, Cephalon Inc, and Millennium Pharmaceuticals Inc

Exploring the Clinical Decisions of US Community-Based Oncologists and Hematologists in the Management of Multiple Myeloma and Follicular Lymphoma
Supported by educational grants from Celgene Corporation, Cephalon Inc, and Millennium Pharmaceuticals Inc

 

To obtain a better understanding of community-based medical oncology practice patterns, 43 oncologists within the United States were recruited to complete a traditional clinical case–based questionnaire and to contribute specific anonymous demographic and treatment information derived from their actual patients. This information was used to create a cross-sectional case database on two types of cancer in which major clinical advances have been reported in recent years - multiple myeloma and follicular lymphoma.

 

To view the complete contents of the supplement, click on the titles of the three articles listed below.

Recent Videos
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
2 experts are featured in this series.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Related Content
James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Serum BCMA May Help Predict Outcomes, Monitor Disease in Multiple Myeloma

Gina Mauro
October 30th 2024
Article

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase

Russ Conroy
October 29th 2024
Article

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status

Russ Conroy
October 29th 2024
Article

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.